Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Kilitch Drugs (India) Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹186.05Fairly Valued by 5.56%vs CMP ₹197.00

P/E (22.8) × ROE (12.5%) × BV (₹80.00) × DY (2.00%)

₹131.28Overvalued by 33.36%vs CMP ₹197.00
MoS: -50.1% (Negative)Confidence: 63/100 (Moderate)Models: 1 Under, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹237.8523%Under (+20.7%)
Graham NumberEarnings₹163.7117%Over (-16.9%)
Earnings PowerEarnings₹9.9011%Over (-95%)
DCFCash Flow₹149.9311%Over (-23.9%)
Net Asset ValueAssets₹80.067%Over (-59.4%)
EV/EBITDAEnterprise₹74.639%Over (-62.1%)
Earnings YieldEarnings₹148.907%Over (-24.4%)
ROCE CapitalReturns₹39.747%Over (-79.8%)
Revenue MultipleRevenue₹56.616%Over (-71.3%)
Consensus (9 models)₹131.28100%Overvalued
Key Drivers: EPS CAGR 27.8% lifts DCF — verify sustainability. | Wide model spread (₹10–₹238) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 27.8%

*Investments are subject to market risks

Analyst Summary

Kilitch Drugs (India) Ltd operates in the Pharmaceuticals segment, NSE: KILITCH | BSE: 524500, current market price is ₹197.00, market cap is 689 Cr.. At a glance, stock P/E is 22.8, ROE is 12.5 %, ROCE is 14.4 %, book value is 80.0, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹131.28, around 33.4% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹198 Cr versus the prior period change of 28.6%, while latest net profit is about ₹25 Cr with a prior-period change of 78.6%. The 52-week range shown on this page is 250/117, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisKilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is…

This summary is generated from the stock page data available for Kilitch Drugs (India) Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

68
Kilitch Drugs (India) Ltd scores 68/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health77/100 · Strong
ROCE 14.4% GoodROE 12.5% GoodD/E 0.11 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
Promoter holding at 63.8% Stable
Earnings Quality65/100 · Strong
OPM expanding (11% → 16%) Improving
Quarterly Momentum70/100 · Strong
Revenue (4Q): +14% YoY GrowingProfit (4Q): +38% YoY StrongOPM: 11.4% (down 4.1% YoY) Margin pressure
Industry Rank65/100 · Strong
P/E 22.8 vs industry 55.1 Cheaper than peersROCE 14.4% vs industry 25.0% Below peers3Y sales CAGR: 20% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily.

Share Price and Basic Stock Data

Last Updated: July 2, 2026, 9:27 pm

Market Cap 689 Cr.
Current Price 197
Intrinsic Value₹131.28
High / Low 250/117
Stock P/E22.8
Book Value 80.0
Dividend Yield0.00 %
ROCE14.4 %
ROE12.5 %
Face Value 10.0
PEG Ratio0.82

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Kilitch Drugs (India) Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Kilitch Drugs (India) Ltd 689 Cr. 197 250/11722.8 80.00.00 %14.4 %12.5 % 10.0
Anuh Pharma Ltd 817 Cr. 81.4 115/66.719.9 35.11.84 %15.9 %12.1 % 5.00
Bafna Pharmaceuticals Ltd 513 Cr. 221 234/77.046.2 40.60.00 %11.9 %12.3 % 10.0
Kopran Ltd 906 Cr. 188 219/10735.2 1101.60 %6.65 %4.91 % 10.0
Albert David Ltd 407 Cr. 715 959/580 6860.70 %0.77 %0.38 % 10.0
Industry Average22,312.53 Cr1,264.6655.12218.190.35%24.95%18.34%6.10

All Competitor Stocks of Kilitch Drugs (India) Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 29.9745.4836.5641.2031.7944.8233.4547.4756.1761.2343.1448.9253.81
Expenses 25.9939.2630.3832.5829.5137.7431.7941.3747.4446.6439.8843.8847.66
Operating Profit 3.986.226.188.622.287.081.666.108.7314.593.265.046.15
OPM % 13.28%13.68%16.90%20.92%7.17%15.80%4.96%12.85%15.54%23.83%7.56%10.30%11.43%
Other Income 0.691.020.560.492.960.472.575.161.731.702.566.661.53
Interest 1.291.211.501.511.601.321.730.311.401.601.531.441.15
Depreciation 0.930.910.710.820.810.930.850.610.810.850.840.860.94
Profit before tax 2.455.124.536.782.835.301.6510.348.2513.843.459.405.59
Tax % 30.61%43.16%32.67%24.93%38.16%30.57%93.33%16.73%32.00%26.23%34.49%14.47%22.90%
Net Profit 1.712.903.065.091.743.680.118.615.6110.222.278.044.31
EPS in Rs 1.402.111.992.711.662.050.774.933.415.941.734.692.53

Last Updated: March 4, 2026, 4:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 6:46 pm

MetricMar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 10819212751825368114140154198207
Expenses 9521252845755363104122130167178
Operating Profit 13-2-4-167051018243229
OPM % 12%-9%-19%-2%11%9%1%8%9%13%16%16%14%
Other Income 9232134433341112
Interest 3000011115656
Depreciation 521010222224333
Profit before tax 97-1-12-969251012193432
Tax % 22%-70%-4%-5%16%55%48%27%35%31%30%28%
Net Profit 76-0-11-9541468142525
EPS in Rs 52.99-0.20-7.77-6.173.462.290.502.184.366.188.3415.2614.89
Dividend Payout % 52%0%0%0%13%20%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)18.18%155.56%-20.00%-75.00%300.00%50.00%33.33%75.00%78.57%
Change in YoY Net Profit Growth (%)0.00%137.37%-175.56%-55.00%375.00%-250.00%-16.67%41.67%3.57%

Kilitch Drugs (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:26%
5 Years:30%
3 Years:20%
TTM:38%
Compounded Profit Growth
10 Years:43%
5 Years:164%
3 Years:60%
TTM:123%
Stock Price CAGR
10 Years:28%
5 Years:33%
3 Years:30%
1 Year:9%
Return on Equity
10 Years:4%
5 Years:8%
3 Years:10%
Last Year:14%

Last Updated: September 5, 2025, 9:05 am

Balance Sheet

Last Updated: July 6, 2026, 2:30 am

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital 131313141515151616161635
Reserves 107958898106103112124136160186245
Borrowings -0011913152022324989
Other Liabilities 7811151312615046326189
Total Liabilities 127117113128144143203210220240313458
Fixed Assets 94233333232306564626467
CWIP -0-01320306534647140
Investments 724953565352607162727275
Other Assets 462526353830477190100129176
Total Assets 127117113128144143203210220240313458

Reserves and Borrowings Chart

Cash Flow

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity + -81711044663-21824
Cash from Investing Activity + -31-20-2-4-14-10-38-158-8-40-100
Cash from Financing Activity + -00-0617127-191382
Net Cash Flow -39-2-023-510-210-1-96
Free Cash Flow -10-26-0-2-19-69-2-1-8-29-76
CFO/OP 430%-442%-202%25%60%1,598%877%79%39%23%82%94%

Free Cash Flow

MonthMar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow13.00-2.00-4.00-2.005.00-2.00-13.00-10.00-10.00-4.00-8.00-17.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 5124328619614886109122132142149156
Inventory Days 12124110843936703528101853
Days Payable 191241541841083389525239200118189
Cash Conversion Cycle 4424324196798989-367-79-485020
Working Capital Days -143197234115933722-223-40-43056
ROCE %8%-10%-9%5%6%1%3%6%10%13%16%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 68.24%68.24%69.23%69.23%69.23%69.23%69.23%69.23%69.23%69.23%63.77%63.77%
Public 31.75%31.76%30.78%30.76%30.77%30.77%30.77%30.76%30.77%30.77%36.22%36.23%
No. of Shareholders 9,5229,5739,0029,0629,5259,6209,92010,1399,74910,37910,92912,043

Shareholding Pattern Chart

No. of Shareholders

Kilitch Drugs (India) Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 16.609.176.714.732.37
Diluted EPS (Rs.) 16.609.176.714.732.37
Cash EPS (Rs.) 17.4410.527.595.573.71
Book Value[Excl.RevalReserv]/Share (Rs.) 125.81109.6296.6490.0383.56
Book Value[Incl.RevalReserv]/Share (Rs.) 125.81109.6296.6490.0383.56
Revenue From Operations / Share (Rs.) 123.3195.9989.5973.3144.22
PBDIT / Share (Rs.) 26.5017.8013.158.525.07
PBIT / Share (Rs.) 24.5715.7210.876.943.79
PBT / Share (Rs.) 21.4412.037.716.173.30
Net Profit / Share (Rs.) 15.518.445.323.992.43
NP After MI And SOA / Share (Rs.) 16.609.086.714.732.37
PBDIT Margin (%) 21.4918.5414.6711.6211.47
PBIT Margin (%) 19.9216.3712.129.468.57
PBT Margin (%) 17.3812.538.608.417.47
Net Profit Margin (%) 12.578.795.935.435.49
NP After MI And SOA Margin (%) 13.469.457.486.445.35
Return on Networth / Equity (%) 13.198.286.895.292.88
Return on Capital Employeed (%) 17.2914.3711.247.694.52
Return On Assets (%) 8.536.084.753.511.80
Long Term Debt / Equity (X) 0.130.000.000.000.00
Total Debt / Equity (X) 0.240.170.140.140.11
Asset Turnover Ratio (%) 0.710.670.650.480.41
Current Ratio (X) 2.062.271.841.651.10
Quick Ratio (X) 1.882.211.811.571.05
Inventory Turnover Ratio (X) 20.5551.1821.1614.048.31
Interest Coverage Ratio (X) 8.464.834.1611.0810.42
Interest Coverage Ratio (Post Tax) (X) 5.953.292.686.185.99
Enterprise Value (Cr.) 619.00638.35218.65272.89130.24
EV / Net Operating Revenue (X) 3.124.141.572.391.90
EV / EBITDA (X) 14.5222.2910.6720.5516.57
MarketCap / Net Operating Revenue (X) 2.934.061.562.291.83
Price / BV (X) 2.873.561.431.880.98
Price / Net Operating Revenue (X) 2.934.061.562.291.83
EarningsYield 0.040.020.040.020.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Kilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1992PLC066718 and registration number is 066718. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 188.57 Cr. and Equity Capital is Rs. 34.96 Cr. for the Year ended 31/03/2026.
INDUSTRYADDRESSCONTACT
PharmaceuticalsC-301/2, M.I.D.C., New Mumbai Maharashtra 400705Contact not found
Management
NamePosition Held
Mr. Mukund P MehtaManaging Director
Mr. Bhavin Mukund MehtaWhole Time Director
Mrs. Mira B MehtaWhole Time Director
Mr. Hemang J EngineerIndependent Director
Mr. Venkita Subramanian RajanIndependent Director
Prof. Vasudev Krishna MurtiIndependent Director
Mr. Dipen J JainIndependent Director

FAQ

What is the intrinsic value of Kilitch Drugs (India) Ltd and is it undervalued?

As of 16 July 2026, Kilitch Drugs (India) Ltd's intrinsic value is ₹131.28, which is 33.36% lower than the current market price of ₹197.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (12.5 %), book value (₹80.0), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Kilitch Drugs (India) Ltd?

Kilitch Drugs (India) Ltd is trading at ₹197.00 as of 16 July 2026, with a FY2026-2027 high of ₹250 and low of ₹117. The stock is currently in the middle of its 52-week range. Market cap stands at ₹689 Cr..

How does Kilitch Drugs (India) Ltd's P/E ratio compare to its industry?

Kilitch Drugs (India) Ltd has a P/E ratio of 22.8, which is below the industry average of 55.12. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Kilitch Drugs (India) Ltd financially healthy?

Key indicators for Kilitch Drugs (India) Ltd: ROCE of 14.4 % is moderate. Dividend yield is 0.00 %.

Is Kilitch Drugs (India) Ltd profitable and how is the profit trend?

Kilitch Drugs (India) Ltd reported a net profit of ₹25 Cr in Mar 2025 on revenue of ₹198 Cr. Compared to ₹6 Cr in Mar 2022, the net profit shows an improving trend.

Does Kilitch Drugs (India) Ltd pay dividends?

Kilitch Drugs (India) Ltd has a dividend yield of 0.00 % at the current price of ₹197.00. The company is currently not paying meaningful dividends.

Last Updated: July 2, 2026, 9:27 pm
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 524500 | NSE: KILITCH
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Kilitch Drugs (India) Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports